Exact Sciences

Madison, Wisconsin, U.S.  All United States companies → — Founded 1995
Point-of-Care Diagnostics Specialty-Focused AI
Gastroenterology Laboratory Medicine Oncology
Gastroenterology AI Lab & Diagnostics Oncology AI
Acquired (by Abbott Laboratories in March 2026)
Website Claim this company

Products

Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Most insured patients pay $0

See all 1 product →

About Exact Sciences

Exact Sciences is a molecular diagnostics company dedicated to the early detection and prevention of cancer, as well as guiding treatment decisions. The company is best known for its non-invasive colorectal cancer screening test, Cologuard, which analyzes stool samples for DNA markers and occult hemoglobin to assess a patient’s risk of colorectal cancer. Cologuard was the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage, revolutionizing colorectal cancer screening.

Beyond colorectal cancer screening, Exact Sciences offers a range of precision oncology tests, including the Oncotype DX portfolio, which provides genomic insights to inform prognosis and guide treatment decisions for various cancers, particularly breast cancer. The company’s strategy involves building a comprehensive cancer platform that spans screening, minimal residual disease detection, and precision oncology, with a pipeline that includes next-generation colorectal screening and blood-based multi-cancer early detection efforts. Exact Sciences collaborates with leading institutions and healthcare providers to distribute its products and is committed to addressing health equity by improving access to cancer screening and education in underserved communities.

Focus Areas

Molecular diagnostics early cancer detection colorectal cancer screening breast cancer recurrence multi-cancer early detection precision oncology genomic testing molecular residual disease testing [1 19 37]

Business Intelligence

TechnologyExactNexus technology platform (unified clinical experience, connects health systems, providers, payers, AI-generated insights), proprietary stool DNA isolation, DNA stability technology, QuARTS technology (Quantitative Allele-specific Real-time Target and Signal Amplification) for DNA biomarker detection [7, 8, 31]

What Physicians Need to Know

Molecular Diagnostics & Early Cancer Detection
Exact Sciences offers a comprehensive portfolio of molecular diagnostic tests for early cancer detection, including non-invasive options. Their focus is on identifying cancer at earlier, more treatable stages. [1, 18, 38, 39]
Colorectal Cancer Screening
Exact Sciences is a leader in non-invasive colorectal cancer screening with the Cologuardu00ae test, which is FDA-approved and covered by Medicare and most major insurers. [1, 14, 39, 40] They are also developing next-generation blood-based colorectal cancer screening methods. [12, 17]
Breast Cancer Recurrence & Treatment Guidance
The Oncotype DX Breast Recurrence Scoreu00ae test is a key offering, providing personalized genomic insights to predict chemotherapy benefit and recurrence risk in early-stage breast cancer, regardless of nodal status. [1, 14, 15, 26, 31, 34, 36, 39]
Multi-Cancer Early Detection (MCED)
Exact Sciences is advancing multi-cancer early detection with their Cancerguardu2122 test, a blood-based test designed to detect over 50 cancer types and subtypes, including aggressive ones, by analyzing DNA methylation and protein biomarkers. [1, 3, 12, 13, 18, 24, 28, 30, 39]
Precision Oncology & Genomic Testing
Their precision oncology portfolio, including the OncoExTrau00ae test, provides comprehensive genomic profiling (DNA and RNA) for advanced solid tumors to guide therapy selection, immunotherapy options, and clinical trial eligibility. [1, 3, 11, 12, 16, 19, 23, 27, 39]
Molecular Residual Disease (MRD) Testing
The Oncodetectu2122 molecular residual disease (MRD) test quantifies circulating tumor DNA (ctDNA) to detect residual cancer after treatment, monitor for recurrence, and inform personalized treatment decisions for various solid tumors. [1, 2, 3, 4, 5, 6, 9, 25, 29, 37, 39]
Hereditary Cancer Testing
The Riskguardu00ae hereditary cancer test assesses risk for common hereditary cancers and cancer-related syndromes by evaluating 59 genes across 11 cancer types, providing actionable results for personalized care planning. [12, 22, 39]
Physician Tip

Exact Sciences' tests offer actionable genomic insights to guide treatment decisions across the cancer care continuum. The Oncotype DX Breast Recurrence Scoreu00ae test is a standard of care for predicting chemotherapy benefit in breast cancer. [1, 14, 15, 26] The Oncodetectu2122 MRD test can detect cancer recurrence earlier than traditional imaging, enabling timely intervention. [4, 5, 6] The OncoExTrau00ae test provides comprehensive genomic profiling to identify actionable variants for advanced solid tumors, aiding in targeted therapy and clinical trial selection. [11, 16, 19] Their ExactNexusu2122 technology platform aims to streamline workflows and integrate solutions into existing health system processes, making ordering and result access easier. [12, 21] Exact Sciences emphasizes informed decision-making, offering various screening options and providing clear information to help physicians and patients choose the best path. [8, 32]

Exact Sciences utilizes its ExactNexusu2122 technology platform to create a unified clinical experience, connecting health systems, providers, payers, and patients. [12, 21] This platform supports easy ordering via the Exact Sciences Provider Hub, EpicCare Link, electronic interfaces, and fax. [21] They are equipped to integrate solutions into existing workflows, aiming to streamline genomic cancer testing and optimize and automate workflows for clinicians and staff. [12, 21] Their bioinformatics infrastructure leverages AWS HealthOmics for efficient processing of large genomic datasets. [20]

Products by Exact Sciences

1 product in the directory

Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Most insured patients pay $0

What the Web Says

Exact Sciences is a cancer diagnostics company known for its Cologuard test. Reviews for the company and its product are mixed. While Cologuard is praised for its convenience as an at-home screening option, concerns exist regarding its accuracy, particularly its false positive and false negative rates for polyps, and potential insurance billing issues. As an employer, Exact Sciences is seen as a fast-growing company with competitive pay and benefits, but some employees report issues with management, communication, and work-life balance.

Overall: Mixed

Strengths

  • Cologuard offers a convenient and non-invasive at-home screening option for colon cancer.
  • Exact Sciences has a motivating mission to combat cancer and a collaborative team environment.
  • The company offers competitive pay and benefits, including potentially free medical care and good time-off packages.
  • Some employees report a positive work-life balance.
  • Opportunities for professional development exist, especially in the diagnostic healthcare space.
  • Cologuard is considered a reasonable alternative for low-risk individuals who cannot undergo a colonoscopy.

Limitations

  • Cologuard has a notable false positive rate, leading to unnecessary colonoscopies and potential surprise bills.
  • Cologuard is less effective at detecting pre-cancerous polyps compared to a colonoscopy.
  • Some employees report negative experiences with management, poor project organization, and communication issues.
  • The hiring process can be challenging, with some candidates reporting negative interview experiences.
  • There are concerns about job security and advancement opportunities within the company.
  • Cologuard is not recommended for individuals with a history of polyps, family history of colon cancer, or high-risk conditions.

Based on reviews from: Reddit, Indeed.com, Facebook, Gastroenterology Consultants of San Antonio, YouTube, Jobstore.com, Capterra, G2

Last updated: 2026-08-25

Videos

News, demos, and interviews about Exact Sciences.

Loading videos...

Videos load interactively. If none appear, search YouTube for Exact Sciences →

View all on YouTube

Press & Coverage

360Dx
Abbott to Acquire Exact Sciences for $23B
Abbott announced in November 2025 its intention to acquire Exact Sciences for $23 billion, marking its entry into the cancer screening and diagnostics market.
2025-11
Exact Sciences
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
Exact Sciences reported record revenue of $878 million for Q4 2025 and $3.25 billion for the full year 2025, driven by strong performance in its screening and precision oncology segments.
2026-02
Business Wire
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests
Exact Sciences celebrated the passage of federal legislation in February 2026 that creates a pathway for Medicare coverage of multi-cancer early detection (MCED) tests, such as their Cancerguardu00ae test.
2026-02
Abbott
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Abbott announced in March 2026 that its acquisition of Exact Sciences was expected to close on March 23, 2026, following receipt of all necessary regulatory clearances.
2026-03
WisPolitics
Exact Sciences: $2.5 million grant to support UW School of Medicine and Public Health
Exact Sciences awarded a $2.5 million grant in March 2026 to the University of Wisconsin School of Medicine and Public Health to establish the James Dahlberg Fund for Cancer Detection and Clinical Integration.
2026-03
MedTech Dive
Abbott reports diagnostics growth since $21B Exact Sciences buy
In Abbott's first full quarter since acquiring Exact Sciences for $21 billion, the company reported over 40% year-over-year sales growth for its diagnostics business in Q2 2026, largely driven by Cologuard sales.
2026-07
Healthcare Dive
Abbott discloses cyberattack on cancer diagnostics business
Abbott disclosed in July 2026 a cyberattack on its cancer diagnostics business, which includes Exact Sciences, with unauthorized access to a limited number of internal systems.
2026-07
PR Newswire
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records
In July 2026, a data breach led to unauthorized access to sensitive patient information from legacy Exact Sciences systems, with the cybercriminal group ShinyHunters claiming responsibility.
2026-07

Frequently Asked Questions

Exact Sciences offers a comprehensive portfolio of molecular diagnostic tests. Key offerings include the Cologuardu00ae and Cologuard Plusu00ae tests for colorectal cancer screening, the Cancerguardu2122 test for multi-cancer early detection, and the Oncotype DXu00ae Breast Recurrence Score test for breast cancer recurrence. [1, 5, 7, 13, 17, 19, 35] For precision oncology, they provide the OncoExTrau2122 therapy selection test for advanced solid tumors and the Oncodetectu2122 test for molecular residual disease (MRD) and recurrence monitoring across various solid tumors. [1, 2, 4, 5, 9, 14, 18, 29, 36]
Exact Sciences' Cancerguardu2122 MCED test is designed for seamless integration into existing workflows and electronic medical records (EMRs), offering comprehensive support for both patients and clinicians. [1] Similarly, the Oncodetectu2122 MRD test process involves the doctor sending a tumor sample to create a personalized profile, followed by blood draws (in-office or at-home) to detect circulating tumor DNA. [24] Exact Sciences aims to streamline testing options and reduce workflow complexities for healthcare providers. [4]
The Cancerguardu2122 test is priced at $689 and may be eligible for flexible spending and health savings account use, with payment plans available. [1] Exact Sciences also offers a patient imaging assistance program to help reduce non-covered imaging costs for eligible patients. [1] For the Oncodetectu2122 MRD test, Exact Sciences states it provides affordable access, with over 91% of patients having $0 out-of-pocket costs and 95% paying less than $100 in financial responsibility. [2]
Exact Sciences offers extensive support through their Provider Hub, enabling physicians to order tests, access results, and receive updates efficiently. [2, 26, 34, 38] They provide resources such as welcome kits, guidelines, and educational materials for tests like the Oncotype DX Breast Recurrence Score test and the Oncodetectu2122 MRD test. [26, 34] Additionally, their patient navigation program for tests like Cologuardu00ae includes patient reminders and tracking for adherence, with interpreter services in over 240 languages. [37]
Exact Sciences has strategic partnerships with various organizations to advance cancer diagnostics. They collaborate with Mayo Clinic on research and development, which led to the invention of the Cologuardu00ae test. [15, 19] They also have agreements with the Broad Institute of MIT and Harvard for next-generation MRD detection technology and with Baylor Scott & White to generate real-world evidence for their multi-cancer early detection approach. [11, 23] Furthermore, Exact Sciences has partnered with Flatiron Health to accelerate clinical evidence generation for the Oncodetectu2122 MRD test and with Humana to expand access to Cologuard Plusu2122. [19, 21]
Exact Sciences is a leading provider of cancer screening and diagnostic tests with a growing portfolio of established brands and innovative solutions. [1, 19, 29] They are committed to investing in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes and transforming the way cancer is detected, diagnosed, and managed. [1, 7, 19, 29] Their collaborations and continuous innovation in areas like multi-cancer early detection and molecular residual disease testing demonstrate a strong commitment to advancing cancer care. [1, 11, 23]

Investors

Who's funded Exact Sciences.

Mayo Clinic Ventures
Corporate VC T3
Rochester, United States
$250k-$1M
Mayo Clinic Ventures is the commercialization and venture arm of Mayo Clinic, investing in companies that align with the institution’s clinical and…
AI/ML in Healthcare Biotech

Related Companies

SOPHiA GENETICS
Rolle, Switzerland and Boston, Massachusetts, United States

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
NTL Healthcare
Seongnam-si, Gyeonggi-do, Republic of Korea

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]
Lumonus
Sydney, Australia

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]
DeepBio
Seoul, South Korea

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CapsoVision
Saratoga, California, United States [1, 2, 11, 13, 17, 19]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]
AIRA Matrix
Thane, Maharashtra, India

AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]
Suggest an Edit → | Report an issue
AI Tool Finder
AI-powered search. Results may not be comprehensive.